pharmaceutical-technology.com Main News

Disruption of the gene should result in humans that are resistant to certain types of viral infection. This research has caused significant ethical debate about the use of gene-editing technologies in the scientific community.

vaccine infection HIV

pharmaceutical-technology.com

02.09.2020 / 13:19

67%

218

Sage’s Zulresso for postpartum depression has uncertain payer coverage

Analysts have been mostly positive on the uptake, and a report noted that Zulresso’s risk evaluation and mitigation strategies (REMS) requirement for continuous 60-hour assessment might complicate uptake, but it should be easily overcome as such monitoring is common practice. However, experts said it will not be issues with REMS that impedes uptake, but the fact that many mothers might be unable to find support to care for their infants while admitted.

Usa experts Pregnancy patient

pharmaceutical-technology.com

01.09.2020 / 17:41

77%

148

Oxford Biomedica enters Covid-19 vaccine manufacturing deal

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.UK-based gene and cell therapy group Oxford Biomedica has entered a supply agreement with AstraZeneca UK for large-scale production of Covid-19 vaccine candidate, AZD1222. The 18-month supply deal is part of a three-year master supply and development agreement between the companies, which may choose to expand the supply period for an additional 18 months into 2022 and 2023.

Britain covid-19 information vaccine

pharmaceutical-technology.com

31.08.2020 / 12:57

59%

767

FDA grants EUA for Gilead’s remdesivir to treat Covid-19

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.The US Food and Drug Administration (FDA) has granted emergency use authorisation (EUA) for Gilead Sciences’ Veklury (remdesivir) to treat all hospitalised patients with Covid-19. Previously, the drug received emergency authorisation for treating patients hospitalised with severe form of the disease.

Usa covid-19 information patient

pharmaceutical-technology.com

31.08.2020 / 12:57

85%

966

Q&A with IQVIA: digital transformation in a post-Covid-19 world

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.The pharma industry – and clinical trials in particular – have been significantly disrupted by the Covid-19 pandemic. For example, lockdowns and social distancing have made it all but impossible for many ill patients to visit their trial sites for monitoring and medication.

covid-19 pandemic information patient

pharmaceutical-technology.com

31.08.2020 / 11:05

44%

110

Sinovac’s Covid-19 vaccine gets emergency use approval in China

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.Sinovac Biotech has received emergency use approval for its potential Covid-19 vaccine CoronaVac under a programme in China to vaccinate high-risk groups, according to Reuters citing a person familiar with the matter. The company started developing the inactivated vaccine against Covid-19 in January this year in alliance with academic research institutes in China.

China covid-19 information vaccine

pharmaceutical-technology.com

28.08.2020 / 11:25

51%

504

Akers, Premas note positive proof-of-concept data of Covid-19 vaccine

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.Akers Biosciences and Premas Biotech have reported positive proof-of-concept data from animal studies of their PRAK-03202 vaccine candidate against Covid-19. A four-week test in mice met its primary endpoints of safety and immune response, said the companies.

covid-19 information vaccine

pharmaceutical-technology.com

27.08.2020 / 16:23

75%

321

EC signs first Covid-19 vaccine contract with AstraZeneca

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.The European Commission (EC) has signed its first contract with AstraZeneca for the supply of a Covid-19 vaccine candidate to the European Union (EU) Member States. Under the contract, EC can purchase the vaccine for all the EU Member States and also to donate to lower and middle-income countries or distribute to other countries in Europe.

Eu city Oxford covid-19 information vaccine

pharmaceutical-technology.com

27.08.2020 / 14:41

49%

343

UQ’s Covid-19 vaccine shows effectiveness in preclinical studies

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.The University of Queensland (UQ) in Australia has reported positive data from preclinical tests of its Covid-19 vaccine candidate conducted by Viroclinics-DDL in the Netherlands. Data indicates the candidate’s effectiveness and manufacturability.

Australia Netherlands virus covid-19 vaccine

pharmaceutical-technology.com

26.08.2020 / 17:27

75%

732

NeuroRx’s RLF-100: the key to treating and preventing Covid-19 respiratory failure?

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.Early in the Covid-19 pandemic, a research and development (R&D) consultant at Swiss pharma company Relief Therapeutics, Yves Sagot, realised that a drug developed in the early 2000s for acute respiratory distress and other lung diseases and acquired by Biogen could be effective at treating Covid-19. Relief then reached out to US-based NeuroRx to help them co-develop this drug for Covid-19, because the latter has a “history of taking already known molecules and moving them very quickly through the FDA”, explains NeuroRx CEO and chairman Professor Jonathan Javitt.

Usa Switzerland county Early virus covid-19 Ventilators patient

pharmaceutical-technology.com

26.08.2020 / 09:45

76%

462

Translate Bio-Sanofi Covid-19 vaccine elicits immune response in animals

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.Translate Bio has reported that its Covid-19 vaccine candidate, being developed in collaboration with Sanofi, elicited immune response in early-stage animal studies. In a regulatory filing, Translate Bio cited Sanofi’s presentation slides, which revealed that three doses of the vaccine candidate triggered neutralising antibodies and T-cell responses in the preclinical tests.

city Sanofi covid-19 testing vaccine

pharmaceutical-technology.com

25.08.2020 / 09:55

50%

249

Innovation’s Brilacidin shows promise in-vitro against Covid-19

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.Innovation Pharmaceuticals has reported promising data from ongoing in-vitro testing of its Brilacidin at a US Regional Biocontainment Laboratory (RBL) to treat Covid-19. Data showed that Brilacidin has a high selectivity index (SI), used to compare the antiviral efficacy between investigational drugs.

Usa covid-19 testing information

pharmaceutical-technology.com

24.08.2020 / 13:53

87%

867

FDA grants EUA for convalescent plasma to treat Covid-19

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.The US Food and Drug Administration (FDA) has granted an emergency use authorisation (EUA) for investigational convalescent plasma to treat hospitalised Covid-19 patients. Following a review of the available scientific evidence, the regulator said that the known and potential benefits outweigh the known and potential risks of the therapy.

Usa covid-19 information patient

pharmaceutical-technology.com

21.08.2020 / 18:41

83%

322

COVID-19: Poll finds business sentiment is improving

optimism regarding future growth prospects has been improving since June, after being low during the early days of the pandemic. The business optimism levels improved to 61.4% during the three months between June and August, compared to 45.3% witnessed between March and May.

covid-19 pandemic economy crisis

pharmaceutical-technology.com

21.08.2020 / 15:07

77%

561

CureVac concludes talks with EC for Covid-19 vaccine supply

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.German biopharmaceutical firm CureVac has concluded exploratory discussions with the European Commission (EC) on an advanced purchase agreement (APA) for the company’s mRNA-based Covid-19 vaccine candidate. The proposed contract will provide all European Union (EU) member states with up to 225 million doses, with an option for an additional of 180 million doses, made if the vaccine candidate is safe and effective.

Germany Eu covid-19 pandemic vaccine

pharmaceutical-technology.com

20.08.2020 / 21:31

80%

523

Concerns over the spread of COVID-19 declining since June: Poll

A majority of 71% of the poll respondents were very concerned about the spread of COVID-19 between March and May.Concern levels during the first three months of the poll were highest between 29 March and 16 April, at 78%, when the novel coronavirus (nCoV) was spreading quickly across borders. The concern levels declined during the first week of May before rising again to more than 70% by the third week.

covid-19 symptoms Coronavirus

pharmaceutical-technology.com

20.08.2020 / 15:59

77%

201

Roche teams up with Regeneron on Covid-19 therapy

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.Roche has partnered with Regeneron Pharmaceuticals to develop, manufacture and distribute the latter’s antiviral antibody combination, REGN-COV2, as a potential treatment of Covid-19. REGN-COV2 could help treat patients with symptoms and also prevent the disease in individuals exposed to the virus.

virus covid-19 prevention patient

pharmaceutical-technology.com

20.08.2020 / 09:49

40%

124

Elicio joins race for Covid-19 vaccine with lymph node targeting candidate

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.Elicio Therapeutics has reported promising findings from preclinical studies of ELI-005, a protein subunit, lymph node targeting Covid-19 vaccine candidate. Data showed that the candidate was able to trigger a ‘high magnitude’ T cell response and potent neutralising antibodies against Covid-19.

covid-19 information vaccine Coronavirus

pharmaceutical-technology.com

19.08.2020 / 15:19

48%

794

Australia signs deal for AstraZeneca’s Covid-19 vaccine

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.The Australian Government has signed an agreement with AstraZeneca for the supply of the company’s Covid-19 vaccine candidate developed by the University of Oxford. This deal will provide the vaccine to every Australian for free, if found to be safe and effective in clinical trials, said the country’s Prime Minister Scott Morrison.

Scott Morrison Australia city Oxford covid-19 vaccine Government

pharmaceutical-technology.com

18.08.2020 / 10:27

68%

667

OSE’s Covid-19 vaccine shows promise in preclinical studies

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.OSE Immunotherapeutics has reported positive data from preclinical and human ex-vivo studies of its Covid-19 vaccine candidate, CoVepiT. The company published the findings online on BioRxiv.

virus covid-19 vaccine

pharmaceutical-technology.com

17.08.2020 / 13:53

66%

636

EC and UK sign agreements for Covid-19 vaccines supply

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.The European Commission (EC) and the UK Government have entered into separate agreements for the supply of potential Covid-19 vaccines. The EC concluded an agreement with AstraZeneca for up to 400 million doses of the Covid-19 vaccine candidate AZD1222.

Italy Germany Britain France Eu Netherlands covid-19 vaccine Government

pharmaceutical-technology.com

14.08.2020 / 18:15

67%

744

UNION therapeutics licences drug technology from TFF Pharmaceuticals

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.UNION therapeutics has signed an agreement with TFF Pharmaceuticals for an exclusive global licence to the latter’s Thin Film Freezing (TFF) technology platform used with niclosamide drug. The TFF platform is intended to improve the solubility and absorption of poorly water-soluble drugs, ideal for generating dry powder particles.

covid-19 information Government

pharmaceutical-technology.com

14.08.2020 / 12:37

81%

829

SK bioscience partners with Novavax on Covid-19 vaccine

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.South Korea-based SK bioscience has entered into a development and supply agreement for Novavax Covid-19 vaccine candidate, NVX-CoV2373. The company intends to supply the vaccine to global markets, including COVAX Facility.

South Korea covid-19 information vaccine

pharmaceutical-technology.com

14.08.2020 / 09:15

86%

856

Biological E. to manufacture Janssen’s Covid-19 vaccine

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.India-based pharmaceutical company Biological E. has signed an agreement with Johnson & Johnson (J&J) unit Janssen Pharmaceutica to manufacture J&J’s Covid-19 vaccine candidate, Ad26.COV2.S.

India covid-19 information vaccine

pharmaceutical-technology.com

13.08.2020 / 14:43

52%

913

Brazil’s Parana state to produce Russia’s Covid-19 vaccine

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.The Russian Direct Investment Fund (RDIF) and the Brazilian state of Parana are set to collaborate to produce and distribute Russia’s registered Covid-19 vaccine, Sputnik V. Under the strategic cooperation agreement, RDIF will work with pharmaceutical companies in the state to help organise the production and distribution of the vaccine in Brazil and other Latin American countries.

Usa Russia Brazil covid-19 information vaccine Coronavirus

pharmaceutical-technology.com

12.08.2020 / 12:23

77%

691

Selva raises $3m to develop novel antiviral against Covid-19

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.California-based Selva Therapeutics has closed a Series A round with $3m raised. The funding for the round came from private investors, including Board of Directors member Kenneth Kelley; other participants of the round were not disclosed.

state California virus covid-19 pneumonia patient

pharmaceutical-technology.com

12.08.2020 / 10:33

73%

166

Russia approves world’s first Covid-19 vaccine

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.Russia has awarded regulatory approval to a Covid-19 vaccine, becoming the first country in the world to register a coronavirus vaccine for use. The vaccine, Sputnik V, reflects the former Soviet Union’s space race successes.

Vladimir Putin Russia Soviet Union covid-19 vaccine Coronavirus

pharmaceutical-technology.com

11.08.2020 / 20:11

53%

911

mRNA vaccines the most promising among emerging COVID-19 vaccines: Poll

A minority 8% of the respondents opined that other types of vaccines are the most promising. The analysis is based on 373 responses received between 08 July and 10 August from readers of Pharmaceutical Technology, a Verdict network site.

virus covid-19 vaccine Coronavirus

pharmaceutical-technology.com

11.08.2020 / 10:35

40%

245

GigaGen develops new class of drugs to treat Covid-19

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.US-based biotechnology company GigaGen has developed a new class of drugs, recombinant hyperimmunes, to potentially treat patients with Covid-19. Hospitals across the country are using convalescent plasma to treat Covid-19.

covid-19 pneumonia information

pharmaceutical-technology.com

10.08.2020 / 14:35

77%

627

Pfizer signs multi-year deal to manufacture Gilead’s remdesivir

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.Pfizer has entered into a multi-year agreement to manufacture and supply Gilead Science’s experimental antiviral drug remdesivir, for the treatment of Covid-19 patients. As part of the deal, Pfizer will provide contract manufacturing services at its McPherson, Kansas facility to produce and supply the drug candidate for Gilead.

Albert Bourla state Kansas county Mcpherson covid-19 innovations vaccine

pharmaceutical-technology.com

10.08.2020 / 12:49

44%

571

Novavax partners with Takeda to develop Covid-19 vaccine in Japan

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.US-based biotechnology firm Novavax has partnered with Takeda Pharmaceutical to develop, manufacture and commercialise its Covid-19 vaccine candidate, NVX‑CoV2373, in Japan. Based on Novavax’s recombinant protein nanoparticle technology, the vaccine candidate is a stable, prefusion protein that includes the company’s Matrix‑M adjuvant.

Japan covid-19 information vaccine

pharmaceutical-technology.com

07.08.2020 / 10:07

91%

258

AstraZeneca signs first deal to supply Covid-19 vaccine in China

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.AstraZeneca partnered with Shenzhen Kangtai Biological Products to manufacture its Covid-19 vaccine candidate in mainland China, marking its first deal to supply in the country. As part of the deal, Shenzhen Kangtai will have an annual production capacity of at least 100 million doses of the vaccine candidate, AZD1222.

China Britain county Oxford covid-19 information vaccine

pharmaceutical-technology.com

06.08.2020 / 15:25

82%

243

Q&A with Valneva: UK Government scales up Covid-19 manufacturing

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.French-headquartered Valneva is one of four companies developing a vaccine against Covid-19 that has signed a supply deal with the UK Government’s Vaccines Taskforce. According to the terms of the deal, Valneva is set to supply 60 million doses of its inactivated whole Covid-19 vaccine candidate, VLA2001, from mid- 2021.

Britain Scotland covid-19 pandemic vaccine Government

pharmaceutical-technology.com

06.08.2020 / 13:23

92%

403

Janssen to supply 100 million Covid-19 vaccine doses to US

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.Johnson & Johnson (J&J) unit Janssen Pharmaceutical has signed an agreement with the US Government for the large scale domestic production and supply of 100 million doses of its Covid-19 vaccine candidate, Ad26.COV2.S. The vaccine, based on Janssen AdVac technology, will be used in the US after it secures regulatory approval or emergency use authorisation.

Usa covid-19 vaccine Government

pharmaceutical-technology.com

06.08.2020 / 11:27

77%

318

Pandemic logistics: resolving manufacturing and distribution challenges

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.Although pricing and allocation pose serious challenges to ensuring access to Covid-19 medicines and vaccines globally, as Mike Piccarreta, partner at consulting firm Kearney, notes: “Delivering a vaccine at a truly global scale will present logistical challenges across all steps of the supply chains.” Big Pharma’s commitments to and mechanisms for equitable access are moot if vaccines and drugs, once approved, cannot actually be manufactured at sufficient scale or be delivered to patients across the world.

covid-19 pandemic information vaccine

pharmaceutical-technology.com

05.08.2020 / 16:39

63%

182

Discussing the UK’s Covid-19 strategy with Kate Bingham, chair of Vaccines Taskforce

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.A central priority of the UK Government in tackling the Covid-19 pandemic is fast-tracking the development of potential treatments and vaccines for this deadly disease. This policy is being carried out by expert-led taskforces, which oversee the development landscape and support promising innovations.

Kate Bingham Britain covid-19 pandemic innovations vaccine

pharmaceutical-technology.com

05.08.2020 / 14:49

66%

665

Improved patient access seen as the main benefit of telemedicine: Poll

A minority 7% of the respondents felt that improved patient engagement was the main benefit. The analysis is based on 323 responses received from the readers of Pharmaceutical Technology, a Verdict network site, between 18 June and 31 July.

covid-19 pandemic doctor patient

pharmaceutical-technology.com

05.08.2020 / 14:49

75%

514

UK and Valneva to invest in coronavirus vaccine manufacturing

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.The UK Government and biotech company Valneva are set to make a joint investment in a manufacturing facility in Livingston, West Lothian as part of an agreement for early access to 60 million doses of the company’s Covid-19 vaccine candidate. The investment will boost vaccine manufacturing capacity Valneva’s Livingston site and support the jobs of more than 100 scientists and technicians.

Britain county Livingston covid-19 vaccine Government Coronavirus

pharmaceutical-technology.com

05.08.2020 / 13:03

92%

765

COVID-19 poll: Disrupted clinical trials will take six to 12 months to return to normal

A majority 27% of the respondents opined that the disrupted clinical trials could take more than 12 months to return to normal, while 23% felt that four to six months may be enough and 22% were optimistic about witnessing normalcy in just three months. Further, 15% of the respondents felt that it could take seven to nine months for disrupted clinical trials to return to normal followed by 13% who felt that it could take ten to 12 months.

covid-19 pandemic patient Coronavirus

pharmaceutical-technology.com

04.08.2020 / 17:29

58%

259

Pandemic logistics: guaranteeing equitable access

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.Since Covid-19 first entered the global psyche in January this year, the pharmaceutical industry has committed itself to developing both vaccines and therapies to prevent and treat this deadly virus. However, Access to Medicine Foundation research programme manager Danny Edwards argues that drug and vaccine development is “only half of the equation”.

covid-19 pandemic vaccine medicines

pharmaceutical-technology.com

03.08.2020 / 18:19

82%

569

Covid-19 pandemic: Russian hackers target UK, US and Canadian research

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.In mid-July, the UK’s National Cyber Security Centre (NCSC) published a report stating that the cyber espionage group, APT29, which is “almost certainly part of the Russian intelligence services”, has been attacking organisations based in the UK, US and Canada that are involved in developing Covid-19 vaccines. This assessment was supported by the Canadian Communication Security Establishment, as well as the US Department for Homeland Security’s Cybersecurity Infrastructure Security Agency and the National Security Agency.

Usa Britain Canada Russia county Canadian covid-19 pandemic vaccine

pharmaceutical-technology.com

03.08.2020 / 16:51

39%

719

UK teams up with Wockhardt for vaccine manufacturing services

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.The UK Government has partnered with India-based pharmaceutical company Wockhardt for ‘fill and finish’ services to boost vaccine manufacturing in the UK. The 18-month agreement is intended to increase capacity for the production of Covid-19 vaccines.

India Britain covid-19 innovations vaccine Government

pharmaceutical-technology.com

03.08.2020 / 13:07

91%

497

Pfizer, BioNTech to supply 120 million Covid-19 vaccine doses to Japan

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.Pfizer and BioNTech have entered into an agreement with Japan’s Ministry of Health, Labour and Welfare (MHLW) to provide 120 million doses of their BNT162 Covid-19 vaccine candidate. While financial details of the deal were not divulged, the terms were said to be based on the delivery timing and the volume of doses; deliveries are planned for the first half of next year.

Japan covid-19 vaccine Department

pharmaceutical-technology.com

31.07.2020 / 17:33

50%

472

US commits $2.1bn for 100 million Sanofi-GSK Covid-19 vaccine doses

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.The US Government has committed to providing up to $2.1bn to Sanofi and GlaxoSmithKline (GSK) for development, manufacturing, scale-up and delivery of an initial 100 million doses of the companies’ Covid-19 vaccine candidate. Based on Sanofi’s recombinant protein technology, the vaccine candidate utilises GSK’s pandemic adjuvant technology.

Usa city Sanofi covid-19 pandemic vaccine Government

pharmaceutical-technology.com

30.07.2020 / 17:25

67%

374

J&J begins first trial of Covid-19 vaccine after positive preclinical data

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.Johnson & Johnson (J&J) has started a Phase I/IIa clinical trial of its Covid-19 vaccine candidate, Ad26.COV2.S, in healthy volunteers across the US and Belgium. The first-in-human trial comes after the vaccine candidate showed promise in preclinical studies, where the product was able to trigger a immune response against SARS-CoV-2.

Beth Israel Usa Israel Belgium virus covid-19 vaccine Volunteers

pharmaceutical-technology.com

30.07.2020 / 15:29

51%

911

Intravacc and Celonic team up to develop Covid-19 vaccine

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.Intravacc has partnered with contract development and manufacturing organisation (CDMO) Celonic Group for the design, development and production of a Covid-19 vaccine. The vaccine will be based on an immunogenic Spike (S) protein of SARS-CoV-2 andIntravacc’s Outer Membrane Vesicle (OMV) technology.

covid-19 information vaccine

pharmaceutical-technology.com

30.07.2020 / 13:03

64%

466

From rare diseases to Covid-19: charting the history of Genomics England

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.In 2003, after 13 years of work and more than £2bn spent, scientists involved in the Human Genome Project mapped the first complete genetic code, or genome, of a human being. This was a huge scientific breakthrough and taught genetics researchers a lot about human genes, the genome and how they interact with health and disease.

covid-19 NHS medicines diseases

pharmaceutical-technology.com

29.07.2020 / 14:19

70%

242

Health Canada authorises remdesivir as first Covid-19 treatment

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.Health Canada has granted conditional approval to Gilead Sciences’ remdesivir (Veklury) to treat patients with severe Covid-19 who have pneumonia and need oxygen support. Remdesivir is the first drug authorised in the country for Covid-19 treatment.

Health Canada Canada covid-19 patient

United States	Cases: 46 252 513 Deaths: 750 423 Recovered: 0
India	Cases: 34 321 025 Deaths: 459 652 Recovered: 0
Brazil	Cases: 21 835 785 Deaths: 608 235 Recovered: 0
United Kingdom	Cases: 9 215 683 Deaths: 141 607 Recovered: 0
Russia	Cases: 8 494 589 Deaths: 237 619 Recovered: 0

pharmaceutical-technology.com Main News

Related News